CLINICAL SIGNIFICANCE OF PENTRAXIN-3 AND C-REACTIVE PROTEIN IN THE DIFFERENTIATION OF STAGES OF NONALCOHOLIC FATTY LIVER DISEASE (25-29)

Список литературы: 1. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5:145–171. 2. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134–140. 3. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012; 30:158–162. 4. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313–1321. 5. Baranova A, Lal P, Birerdinc A, Younossi ZM. Noninvasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91. 6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38: 1449–1457. 7. Anty R, Iannelli A, Patouraux S, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32: 13151322. 8. Ratziu V, Charlotte F, Heurtier F, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 18981906. 9. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46:582–589. 10. Targher G. Relationship between highsensitivity C-reactive protein levels and liver histology in subjects with nonalcoholic fatty liver disease. J Hepatol 2006; 45:879–881. 11. Yoneda M, Uchiyama T, Kato S, et al. Plasma pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008; 8: 53. 12. Pepys M B, Hirschfield G M. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805– 1812. 13. Bottazzi B, Garlanda C, Cotena C, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009; 227:9–18. 14. Deniz T, Kizilgul M, Uzunlulu M, et al. Levels of Pentraxin 3 and relationship with disease activity in patients with ankylosing spondylitis. Acta Reumatol Port 2014; 39:137–142. 15. Zhang J, Shan L, Koussih L, et al. Pentraxin 3 (PTX3) expression in allergic asthmatic airways: role in airway smooth muscle migration and chemokine production. PLoS One 2012; 7:1–9. 16. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349–2354 17. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29:1404–1407.